H. Klafki

发表

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

Claudio Babiloni, Fabrizio Vecchio, Beatriz Bosch, 2011, Journal of Alzheimer's disease : JAD.

Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data

H. Soininen, J. Kassubek, S. Herukka, 2016, Scientific Reports.

Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease

J. Wiltfang, A. Kribben, D. Hermann, 2015, Molecular Neurobiology.

Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands

H. Klafki, H. Tumani, M. Otto, 2015, Electrophoresis.

High-fat diet induced isoform changes of the Parkinson's disease protein DJ-1.

W. Wurst, J. Wiltfang, K. Stühler, 2014, Journal of proteome research.

Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.

J. Wiltfang, H. Klafki, G. Jennings, 2010, Chemistry.

Inhibition of PHF-like tau hyperphosphorylation in SH-SY5Y cells and rat brain slices by K252a.

H. Klafki, H. Roder, Sandrine Ferrand, 2008, Journal of Alzheimer's disease : JAD.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

T. Bayer, J. Wiltfang, O. Wirths, 2017, Alzheimer's Research & Therapy.

Deposition of C-terminally truncated A beta species A beta 37 and A beta 39 in Alzheimer ' s disease and transgenic mouse models

A. Paetau, T. Bayer, J. Wiltfang, 2022 .

Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples.

W. Wurst, J. Wiltfang, K. Stühler, 2013, Analytical biochemistry.

Electrophoretic Separation of βA4 Peptides (1–40) and (1–42)

M. Staufenbiel, H. Klafki, J. Wiltfang, 1996 .

Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation

J. Schuchhardt, J. Wiltfang, S. Palme, 2022, Alzheimer's research & therapy.

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2010, Journal of Neuroinflammation.

N-Terminal Truncated Aβ4-42 Is a Substrate for Neprilysin Degradation in vitro and in vivo.

T. Bayer, J. Wiltfang, O. Wirths, 2019, Journal of Alzheimer's disease : JAD.

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

J. Schuchhardt, J. Wiltfang, O. Wirths, 2022, Fluids and Barriers of the CNS.

Urea‐based two‐dimensional electrophoresis of beta‐amyloid peptides in human plasma: Evidence for novel Aβ species

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2007, Proteomics.

Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.

J. Wiltfang, H. Klafki, Ute Haussmann, 2012, Organic & biomolecular chemistry.

Therapeutic approaches to Alzheimer's disease.

Johannes Kornhuber, Jens Wiltfang, J. Kornhuber, 2006, Brain : a journal of neurology.

Smoking behaviour is associated with expression and phosphorylation of CREB in human buffy coat.

G. Winterer, J. Kornhuber, H. Frieling, 2010, The international journal of neuropsychopharmacology.

Immune complexes of auto-antibodies against Aβ1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2007, Molecular Psychiatry.

CSF amyloid‐β 1‐38 and 1‐42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2008, Proteomics. Clinical applications.

A quantitative CE method to analyse tau protein isoforms using coated fused silica capillaries.

J. Wiltfang, H. Klafki, M. Taverna, 2010, Journal of separation science.

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2021, Frontiers in Molecular Neuroscience.

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

J. Wiltfang, O. Wirths, Isabella Ogorek, 2021, Alzheimer's research & therapy.

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

J. Wiltfang, O. Wirths, C. Stadelmann, 2018, Acta Neuropathologica Communications.

ERK1/2 protein and mRNA levels in human blood are linked to smoking behavior

G. Winterer, J. Kornhuber, H. Frieling, 2012, Addiction biology.

The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus

H. Grallert, J. Hebebrand, A. Hinney, 2018, Obesity Facts.

N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease

T. Bayer, J. Wiltfang, O. Wirths, 2020, Neuropathology and applied neurobiology.

Micro-droplet arrays for micro-compartmentalization using an air/water interface.

J. Kutter, H. Klafki, M. Dufva, 2018, Lab on a chip.

cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases

K. Blennow, H. Soininen, L. Buée, 2010, International journal of Alzheimer's disease.

ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients.

J. Wiltfang, H. Kretzschmar, H. Klafki, 2010, Journal of Alzheimer's disease : JAD.

Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay

J. Wiltfang, H. Klafki, M. Otto, 2015, Scientific Reports.

Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2015, Neurobiology of Disease.

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia

J. Schuchhardt, J. Wiltfang, L. Parnetti, 2011, International journal of Alzheimer's disease.

Clinical Study Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in

J. Schuchhardt, J. Wiltfang, L. Parnetti, 2011 .

Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model

D. Liebetanz, O. Wirths, H. Klafki, 2016, Translational psychiatry.

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.

N. Plesnila, D. Dickson, M. Hutton, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

A. Paetau, T. Bayer, J. Wiltfang, 2016, Acta neuropathologica communications.

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

F. Jessen, I. Heuser, P. Lewczuk, 2010, Molecular Psychiatry.

Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples

J. Wiltfang, O. Wirths, O. Jahn, 2020, International journal of molecular sciences.

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

J. Kornhuber, T. Dyrks, H. Klafki, 2002, Journal of neurochemistry.

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Johannes Kornhuber, Markus Otto, Jens Wiltfang, 2009, Journal of Neural Transmission.

Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases

Philip Scheltens, Hanne Struyfs, Jens Wiltfang, 2016, Journal of neurochemistry.

Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid

J. Wiltfang, B. Mollenhauer, O. Wirths, 2022, Journal of neurochemistry.

Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease.

Klaus Gerwert, Jens Wiltfang, J. Wiltfang, 2016, Analytical chemistry.

β-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor Protein (APP) Transgenic Mice

J. Wiltfang, M. Staufenbiel, W. Möbius, 2011, The Journal of Biological Chemistry.

Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.

J. Schuchhardt, J. Wiltfang, H. Klafki, 2016, Journal of Alzheimer's disease : JAD.

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias

J. Wiltfang, H. Klafki, H. Esselmann, 2012, European Archives of Psychiatry and Clinical Neuroscience.

N-truncated Aβ2-X starting with position two in sporadic Alzheimer's disease cases and two Alzheimer mouse models.

T. Bayer, J. Wiltfang, O. Wirths, 2015, Journal of Alzheimer's disease : JAD.

Analysis of amino-terminal variants of amyloid-β peptides by capillary isoelectric focusing immunoassay.

J. Schuchhardt, J. Wiltfang, H. Zetterberg, 2013, Analytical chemistry.

Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease.

H. Klafki, M. Otto, M. Taverna, 2008, Journal of chromatography. A.

Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions

J. Wiltfang, D. Wedekind, H. Klafki, 2018, Journal of Alzheimer's disease : JAD.

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

P. Lewczuk, E. Rüther, J. Kornhuber, 2006, Brain : a journal of neurology.

Improved electrophoretic separation and immunoblotting of beta‐amyloid (Aβ) peptides 1–40, 1–42, and 1–43

J. Kornhuber, M. Staufenbiel, H. Klafki, 1997, Electrophoresis.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

T. Bayer, J. Wiltfang, O. Wirths, 2017, Alzheimer's Research & Therapy.

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

J. Schuchhardt, J. Wiltfang, O. Wirths, 2018, Alzheimer's Research & Therapy.

Solid‐Phase Synthesis and Characterization of N‐Terminally Elongated Aβ−3–x‐Peptides

J. Wiltfang, N. Rezaei-Ghaleh, O. Jahn, 2016, Chemistry.

Adherence-dependent shifts in the patterns of β-amyloid peptides secreted by human mononuclear phagocytes

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2008, Brain, Behavior, and Immunity.

Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma.

J. Wiltfang, H. Klafki, Jonathan Vogelgsang, 2018, Methods in molecular biology.

Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease

J. Wiltfang, A. Kribben, D. Hermann, 2016, Molecular Neurobiology.

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

A. Paetau, T. Bayer, J. Wiltfang, 2016, Acta Neuropathologica Communications.

Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease

J. Wiltfang, A. Kribben, H. Bruck, 2015, Molecular Neurobiology.

Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.

F. Jessen, I. Heuser, P. Lewczuk, 2009, Journal of Alzheimer's disease : JAD.

ePoster Session

J. Wiltfang, G. Waldemar, A. Kribben, 2017, European Journal of Neurology.

A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model

O. Wirths, H. Klafki, T. Meyer, 2023, International journal of molecular sciences.

CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2006 .

An infrared sensor analysing label‐free the secondary structure of the Abeta peptide in presence of complex fluids

J. Wiltfang, K. Gerwert, H. Klafki, 2016, Journal of biophotonics.

A method to prevent cross contamination during 2‐DE by β‐amyloid peptides

J. Wiltfang, H. Klafki, P. Spitzer, 2010, Proteomics.

Distinct fractional Aβ release patterns in human mononuclear phagocytes

P. Lewczuk, J. Kornhuber, J. Wiltfang, 2009, Journal of Neuroimmunology.

Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS

J. Wiltfang, O. Wirths, O. Jahn, 2023, Journal of the American Society for Mass Spectrometry.

Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice

O. Wirths, S. Weggen, O. Jahn, 2023, Life.

Therapeutic approaches to Alzheimer's disease.

J. Kornhuber, J. Wiltfang, M. Staufenbiel, 2006, Brain : a journal of neurology.

Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples.

H. Klafki, H. Meyer, G. Poschmann, 2013, Analytical biochemistry.

Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.

J. Schuchhardt, J. Wiltfang, H. Klafki, 2016, Journal of Alzheimer's disease : JAD.

Blood plasma biomarkers for Alzheimer’s disease: Aβ1–42/1–40 vs. AβX–42/X–40

H. Klafki, H. Esselmann, Olaf Jahn, 2023, Clinical Chemistry and Laboratory Medicine.

Complete Amino-Acid Sequence of a Lambda Amyloid Fibril Protein Isolated from the Liver of Amyloidosis Patient DIA

N. Hilschmann, H. Klafki, K. Eckart, 1991 .

Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease.

J. Schuchhardt, H. Klafki, C. Bauer, 2024, European archives of psychiatry and clinical neuroscience.

Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.

J. Wiltfang, H. Klafki, Ute Haussmann, 2012, Organic & biomolecular chemistry.